Among them, CX3CL1 expression was significantly correlated with OS in hepatocellular carcinoma patients (low vs. high expression, 609 vs. 429 days, P = 0.0338), whereas there was no statistically significant difference in PFS (low vs. high expression, 225 vs. 192 days, P = 0.0825). This evidence concerns the gene CX3CL1 and hepatocellular carcinoma.